Traders Buy High Volume of Call Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 98,415 call options on the stock. This represents an increase of 240% compared to the average daily volume of 28,932 call options.

Analysts Set New Price Targets

A number of analysts have commented on TEVA shares. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Barclays upped their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Finally, UBS Group upped their target price on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.63.

Check Out Our Latest Stock Analysis on TEVA

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the fourth quarter. Vontobel Holding Ltd. now owns 687,261 shares of the company’s stock valued at $15,147,000 after purchasing an additional 58,772 shares during the last quarter. Asset Management One Co. Ltd. increased its holdings in Teva Pharmaceutical Industries by 14.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock valued at $10,414,000 after buying an additional 58,413 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $104,000. Allspring Global Investments Holdings LLC increased its holdings in Teva Pharmaceutical Industries by 2,018.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company’s stock valued at $23,368,000 after buying an additional 1,045,305 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC increased its holdings in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 154,249 shares of the company’s stock valued at $3,400,000 after buying an additional 10,310 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA opened at $18.60 on Thursday. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a 52 week low of $11.48 and a 52 week high of $22.80. The firm’s fifty day moving average is $19.97 and its 200-day moving average is $18.48.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 5.73% and a positive return on equity of 42.92%. Research analysts forecast that Teva Pharmaceutical Industries will post 2.37 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Further Reading

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.